Table 3.
Risk Factors for Mortality 60 Days After Influenza Diagnosis in HM Patients (n=190)
| Number of patients (%) |
||||||
|---|---|---|---|---|---|---|
|
|
||||||
| Characteristic | Alive (n=160) |
Dead (n=30) |
Unadjusted OR (95% CI) |
P | Adjusted OR (95% CI) |
P |
| Age | 49 (1–88)a | 52 (13–75)a | 1.13 (0.92–1.38)b | 0.246 | 1.10 (0.78–1.55)b | 0.577 |
| Sex | 0.664 | 0.455 | ||||
| Female | 60 (38) | 10 (33) | 1.00 | 1.00 | ||
| Male | 100 (62) | 20 (67) | 1.20 (0.53–2.73) | 0.65 (0.21–2.02) | ||
| Influenza season | 0.470 | 0.605 | ||||
| H1N1 (April 2009–May 2010) | 48 (30) | 11 (37) | 1.00 | 1.00 | ||
| Post-H1N1 (November 2010–February 2014) | 112 (70) | 19 (63) | 0.74 (0.33–1.67) | 0.74 (0.23–2.34) | ||
| Type of malignancy | 0.018 | 0.113 | ||||
| Leukemia | 92 (58) | 10 (33) | 1.00 | 1.00 | ||
| Lymphoma/myeloma | 68 (42) | 20 (67) | 2.71 (1.19–6.15) | 2.37 (0.82–6.88) | ||
| Cancer status | 0.030 | 0.586 | ||||
| Remission | 43 (27) | 2 (7) | 1.00 | 1.00 | ||
| Active/relapse | 117 (73) | 28 (93) | 5.15 (1.18–22.52) | 1.63 (0.28–9.39) | ||
| Corticosteroid use | 0.009 | 0.574 | ||||
| No | 123 (77) | 16 (53) | 1.00 | 1.00 | ||
| Yes | 37 (23) | 14 (47) | 2.91 (1.30–6.51) | 1.37 (0.46–4.14) | ||
| BMI | 0.226 | 0.181 | ||||
| Normal/underweight | 61 (38) | 15 (50) | 1.00 | 1.00 | ||
| Overweight/obese | 99 (62) | 15 (50) | 0.62 (0.28–1.35) | 0.47 (0.16–1.41) | ||
| Neutropenia | 0.140 | 0.477 | ||||
| No | 131 (86) | 21 (14) | 1.00 | 1.00 | ||
| Yes | 29 (76) | 9 (24) | 1.94 (0.80–4.66) | 1.64 (0.42–6.43) | ||
| Lymphocytopenia | 0.140 | 0.995 | ||||
| No | 131 (82) | 21 (70) | 1.00 | 1.00 | ||
| Yes | 29 (18) | 9 (30) | 1.94 (0.80–4.66) | 0.99 (0.26–3.80) | ||
| Decreased albumin level | <0.001 | 0.423 | ||||
| No | 108 (68) | 7 (23) | 1.00 | 1.00 | ||
| Yes | 52 (32) | 23 (77) | 6.82 (2.75–16.93) | 1.65 (0.49–5.57) | ||
| Elevated creatinine level | 0.020 | 0.041 | ||||
| No | 136 (85) | 20 (67) | 1.00 | 1.00 | ||
| Yes | 24 (15) | 10 (33) | 2.83 (1.18–6.79) | 3.33 (1.05–10.56) | ||
| Hypoxia at diagnosis | <0.001 | 0.036 | ||||
| No | 131 (82) | 8 (27) | 1.00 | 1.00 | ||
| Yes | 27 (17) | 22 (73) | 13.34 (5.38–33.12) | 5.87 (1.12–30.77) | ||
| Antiviral therapy within 24 hours of onset of symptoms | 0.665 | 0.951 | ||||
| No | 143 (89) | 26 (87) | 1.00 | 1.00 | ||
| Yes | 17 (11) | 4 (13) | 1.29 (0.40–4.16) | 1.05 (0.20–5.54) | ||
| Respiratory co-infection | 0.003 | 0.010 | ||||
| No | 142 (89) | 20 (67) | 1.00 | 1.00 | ||
| Yes | 18 (11) | 10 (33) | 3.94 (1.60–9.74) | 6.30 (1.55–25.67) | ||
| Center | <0.001 | 0.369 | ||||
| 1 | 125 (78) | 10 (33) | 1.00 | 1.00 | ||
| 2 | 35 (22) | 20 (67) | 7.14 (3.06–16.65) | 2.26 (0.38–13.35) | ||
a
Median (range),
b
interval of 10 years,
c
data available for 188 patients only